CareDx, Inc (NASDAQ:CDNA) Director Ralph Snyderman Sells 2,511 Shares

CareDx, Inc (NASDAQ:CDNA) Director Ralph Snyderman sold 2,511 shares of the company’s stock in a transaction that occurred on Friday, May 28th. The shares were sold at an average price of $81.08, for a total value of $203,591.88. Following the completion of the sale, the director now owns 58,549 shares in the company, valued at $4,747,152.92. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Ralph Snyderman also recently made the following trade(s):

  • On Tuesday, June 1st, Ralph Snyderman sold 2,512 shares of CareDx stock. The shares were sold at an average price of $77.30, for a total value of $194,177.60.

Shares of NASDAQ:CDNA opened at $92.78 on Friday. CareDx, Inc has a twelve month low of $29.85 and a twelve month high of $99.83. The stock’s 50 day moving average price is $76.08. The firm has a market capitalization of $4.83 billion, a price-to-earnings ratio of -319.92 and a beta of 0.67.

CareDx (NASDAQ:CDNA) last issued its earnings results on Wednesday, May 5th. The company reported ($0.01) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.13. CareDx had a negative return on equity of 4.25% and a negative net margin of 6.14%. The company had revenue of $67.40 million for the quarter, compared to analyst estimates of $60.77 million. On average, sell-side analysts anticipate that CareDx, Inc will post -0.33 EPS for the current fiscal year.

Several equities analysts have issued reports on the company. The Goldman Sachs Group assumed coverage on CareDx in a research note on Thursday, June 3rd. They issued a “buy” rating and a $95.00 price target on the stock. Zacks Investment Research raised CareDx from a “sell” rating to a “hold” rating in a research note on Tuesday, April 27th. HC Wainwright lowered CareDx from a “buy” rating to a “neutral” rating in a research note on Friday, February 26th. TheStreet raised CareDx from a “d” rating to a “c-” rating in a research note on Friday, March 19th. Finally, Raymond James dropped their price target on CareDx from $98.00 to $90.00 and set a “strong-buy” rating on the stock in a research note on Thursday, May 6th. Two equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $76.13.

Large investors have recently modified their holdings of the company. Cowa LLC acquired a new position in shares of CareDx during the fourth quarter worth approximately $32,000. Capital Asset Advisory Services LLC purchased a new stake in CareDx in the 4th quarter valued at $32,000. IFP Advisors Inc raised its position in CareDx by 16,600.0% in the 1st quarter. IFP Advisors Inc now owns 501 shares of the company’s stock valued at $34,000 after buying an additional 498 shares during the last quarter. Advisory Services Network LLC raised its position in CareDx by 22.0% in the 4th quarter. Advisory Services Network LLC now owns 638 shares of the company’s stock valued at $46,000 after buying an additional 115 shares during the last quarter. Finally, Captrust Financial Advisors purchased a new stake in CareDx in the 1st quarter valued at $48,000.

CareDx Company Profile

CareDx, Inc discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It offers AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; and AlloSure Heart, a dd-cfDNA test to identify underlying cell injury leading to organ rejection.

See Also: CBOE Russell 2000® Volatility Index

Insider Buying and Selling by Quarter for CareDx (NASDAQ:CDNA)

Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter.